Ultralife Corporation Reports Results of 2026 Annual Shareholder Meeting
Ultralife Corporation (NASDAQ: ULBI), a leading provider in the miscellaneous electrical machinery and equipment sector, has released the official results of its 2026 Annual Meeting of Stockholders, held on July 22, 2026. This report outlines the key decisions and voting outcomes that could have an impact on the company’s future operations and, potentially, its share price.
Key Highlights from the Annual Meeting
- Strong Shareholder Engagement: Out of 16,656,669 outstanding shares entitled to vote as of the record date (May 28, 2026), a significant 83.93% (13,980,794 shares) were represented in person or by proxy, meeting the quorum requirement for the meeting.
Matters Voted Upon and Results
-
Election of Directors
- All five nominated directors were elected to serve one-year terms, until the next annual meeting or until their successors are duly elected and qualified.
- For example, Bradford T. Whitmore received 10,912,209 votes in favor, 368,260 votes withheld, and 2,700,325 broker non-votes. Similar strong support was shown for the other directors, indicating broad investor confidence in current board leadership.
-
Ratification of Independent Auditor
- Shareholders ratified WithumSmith+Brown, PC as the Company’s independent registered public accounting firm for fiscal year 2026.
- Votes in favor: 13,830,508; Votes against: 137,166; Abstentions: 13,120.
- The overwhelming support for the appointment signals confidence in the company’s financial oversight and governance practices.
-
Advisory Vote on Executive Compensation (“Say on Pay”)
- Shareholders approved, on an advisory basis, the executive compensation program.
- Votes in favor: 11,203,815; Votes against: 2,712,560; Abstentions: 64,394; Broker non-votes: 2,700,325.
- This approval suggests investor satisfaction with how Ultralife is compensating its top executives, which is a key factor in aligning management interests with those of shareholders.
-
Advisory Vote on Frequency of Executive Compensation Vote
- Shareholders indicated their preference for a “Say on Pay” vote to be held every three years, rather than annually or biennially.
- Votes for 1 year: 2,576,450; For 2 years: 40,457; For 3 years: 8,663,562; Abstain: 64,394.
- As a result, the Board of Directors has determined that future advisory votes on executive compensation will be held every three years.
Additional Information
- No written communications, soliciting material, or pre-commencement tender offers were included with this filing, and Ultralife is not classified as an emerging growth company.
- The company’s common stock continues to trade on the NASDAQ under the symbol “ULBI”.
Potential Price-Sensitive Developments
- Board Stability: The clear re-election of all directors affirms strategic stability and continuity in oversight—a positive for investor confidence.
- Strong Auditor Support: The near-unanimous ratification of WithumSmith+Brown, PC signals continued trust in the company’s financial reporting, which is crucial for institutional investors and could reduce perceived risk.
- Shareholder Support for Executive Pay: The advisory approval of executive compensation, paired with a triennial frequency for say-on-pay votes, suggests shareholders are largely satisfied with management’s performance and compensation, minimizing the risk of governance disputes or activist challenges in the near term.
Conclusion
The 2026 Annual Meeting results reinforce the current leadership’s mandate and governance practices, with no surprises or shareholder revolts. The Board’s decision to move to a three-year “Say on Pay” vote cycle is in line with the expressed shareholder preference, which may help further align management with long-term investor interests. While no immediate, dramatic price-sensitive events were reported, the clear show of support for both the board and executive pay could be viewed positively by the market and support share value stability.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should review all available information and consult their financial advisors before making any investment decisions. The author does not hold any position in Ultralife Corporation at the time of writing.
